Back
Compare AU
Compare VVLU vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard Global Value Equity Active ETF (VVLU) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VVLU | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 136 | 80 |
Median incremental investment | $1,710.84 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $8,477.90 | $2,210.88 |
Average age group | > 35 | > 35 |
Key Summary
VVLU | DRUG | |
|---|---|---|
Strategy | VVLU.AX was created on 2018-04-13 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Global Value Equity Active ETF (Managed Fund) seeks to provide long term capital appreciation through an active management approach that invests in global equity securities demonstrating value characteristics | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 184.38m in AUM and 55 holdings. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Comcast Corp. Class A (0.72 %) Verizon Communications Inc. (0.62 %) General Motors Co. (0.59 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Financials (30.07 %) Energy (14.49 %) Industrials (11.98 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (67.31 %) Japan (6.67 %) United Kingdom of Great Britain and Northern Ireland (4.16 %) | United States (72.30 %) Switzerland (11.31 %) United Kingdom of Great Britain and Northern Ireland (5.57 %) |
Management fee | 0.28 % | 0.57 % |
Key Summary
VVLU | DRUG | |
|---|---|---|
Issuer | Vanguard | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.28 % | 0.57 % |
Price | $86.72 | $9.95 |
Size | $1.613 billion | $199.202 million |
10Y return | N/A | 112.15 % |
Annual distribution yield (5Y) | 6.00 % | 1.82 % |
Market | ASX | ASX |
First listed date | 17/04/2018 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VVLU | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 136 | 80 |
Median incremental investment | $1,710.84 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $8,477.90 | $2,210.88 |
Average age group | > 35 | > 35 |
Pros and Cons
VVLU | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VVLU | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |